OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
M&A Transactions
M&A Transaction Chart
Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.
Week ended 10/27/2023
Week ended 10/27/2023
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
M&A Transactions Commentary
Week ended 10/27/2023
- The Most Interesting M&A Deal of the Week:
- On October 23, 2023, Cybin (CYBN: NYSE), the fourth largest psychedelics company in the Viridian Value Tracker database, completed its acquisition of Small Pharma (DMT: TSX).
- The consideration includes $37.91M in Cybin shares, representing 4.4x Small Pharma’s book value as of May 2023. The multiple paid is significantly higher than the median market-to-book of 0.85x for the peer group.
- Small Pharma has a complementary research program in DMT and deuterated DMT molecules for use in the treatment of depression. The two companies have “multiple opportunities” for operational and cost synergies.
Week ended 10/27/2023
This is the MA basic
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.